Leading its current growth is Victoza, a GLP-1 injectable which is used by type 2 diabetes patients, and which now outsells its biggest insulin product, Levemir, which saw its revenues decline in ...

This is largely thanks to strong performances from GLP-1 analogue Victoza, insulin analogue Levemir and the 2015 launch of longer-acting insulin analogue Tresiba. Other companies rising strongly ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

Minnesota Attorney General Keith Ellison on Monday announced a settlement in a lawsuit against insulin manufacturer Novo Nordisk. Minnesota residents will now be able to get Novo Nordisk insulin ...

It also caps insulin costs at $35 per month for Medicare beneficiaries and a $2,000 out-of-pocket annual cap for people enrolled in a certain drug plan. Trump's reversal of the 2022 "Lowering ...